openPR Logo
Press release

Antiviral nasal spray said to inactivate coronavirus in 1 minute

03-04-2021 11:08 AM CET | Health & Medicine

Press release from: The Harrington Post

MELBOURNE, Australia -- An antiviral nasal spray approved for European sale inactivates the coronavirus within one minute of use, the spray’s maker says.

Viraleze, available over the counter in Europe and the United Kingdom starting this month, is more than 99% effective in stopping the coronavirus, says Australian pharmaceutical company Starpharma Holdings Ltd., citing in-vitro studies paid for in part by the Australian government.

But the spray is meant to supplement COVID-19 vaccines, masks and other protective measures, not replace them, Starpharma says.

“If you are about to walk into the supermarket, you would use it,” says Starpharma Chief Executive Officer Jackie Fairley. “The same is true for public transport, elevators, planes, bars and restaurants.”

The spray is not absorbed into the bloodstream, she adds.

It can be stored at room temperature and requires no specialized transportation, the Melbourne company says.

Viraleze’s active ingredient is known as SPL7013, or astodrimer sodium.

When Viraleze is sprayed into the nose, the SPL7013 in it works by trapping “spike” proteins protruding from the surface of the coronavirus.

The nasal cavity is the main place where the coronavirus typically establishes itself before spreading to the lungs. The spike proteins, which look like a crown protruding from the outer edge of the virus, give coronaviruses their name.

Once the SPL7013 traps the proteins, “the virus is irreversibly blocked and can no longer infect mucosal cells, thereby providing a physical barrier to respiratory viruses in the nasal cavity,” Starpharma says in a statement.

The blocked coronavirus is then “eliminated naturally through the nasal mucus,” Starpharma says.

Without protection, the coronavirus spike proteins latch onto human cells, then change their physical structure to let the viral membrane fuse with the cell membrane. The coronavirus genes then enter the host cells and are copied, producing more viruses.

“SPL7013 has been shown to be virucidal, rapidly inactivating >99.9% of SARS-CoV-2 within 60 seconds,” Starpharma says. “SARS-CoV-2” is the formal name of the coronavirus that causes COVID-19.

The company did not say if SPL7013 was found to work equally well with coronavirus variants. Some new variants are more transmissible than the original and may be more infectious, studies indicate. They may also be less susceptible to some vaccines than the original coronavirus.

SPL7013 has broad antiviral action and Starpharma says it is also studying the possibility of using SPL7013 to help prevent the spread of HIV, the human papillomavirus and herpes viruses.

The Harrington Post
57 Fairmont Avenue
Kingston, New York 12401
USA
gerryharrington@mindspring.com

Provider of healthcare and related news

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antiviral nasal spray said to inactivate coronavirus in 1 minute here

News-ID: 2251821 • Views: 590

More Releases for Starpharma

Bacterial Vaginosis Drug Market to See Ongoing Evolution 2027 | Bayer, Pfizer, S …
Stratagem Market Insights has announced the addition of the "Bacterial Vaginosis Drug Market Report 2020-2027 Production, Sales And Consumption Status And Prospects Professional Research", The report classifies the global Bacterial Vaginosis Drug Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. The Bacterial Vaginosis Drug Market report is a compilation of first-hand information, qualitative and competitive assessment industry analysts,
Bacterial Vaginosis Drug Market 2020-2025 | In-Depth Analysis with Top Key Vendo …
New Market Research Study on 'Global Bacterial Vaginosis Drug Market' By Investment, Future Demand and Strategic Analysis now Available at "Analytical Research Cognizance" Market Overview The global Bacterial Vaginosis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.1% in the forecast period of 2020 to 2025 and will expected to reach USD 996.5 million by 2025, from USD 883.3
Dendrimers and Polymer Drugs Conjugate Market Detailed Study Analysis with Forec …
Dendrimers, and polymer drug conjugates are nano–sized medicines used for therapeutic applications. In polymer drug conjugates, polymers are covalently bonded to the drug molecule and the linkers are biologically active. Dendrimers are highly water soluble, polyvalent, and have precise molecular weight. They act as carriers of drugs, and facilitate their administration in the body. Dendrimers also have other applications in diagnostic analyses, target therapy, and vaccines. They are also used
Nanomedicines Market Set to Grow at High CAGR by 2027 - AstraZeneca, Cristal The …
The nanomedicines market is anticipated to grow in the forecast period owing to driving factors such as, large amount of R&D happen in this field and the rising number of cases of cancer. The new applications of nanodevices are expected to offer significant growth opportunities in the global nanomedicines market during the forecast period. The global nanomedicines market is expected to witness high growth during the forecast period. The report provides
Nanomedicines Market Significant Growth Opportunities with Futuristic Trends by …
Nanomedicine involves the use of nanoscale materials, such as biocompatible nanoparticles and nanorobots, for diagnosis, delivery, sensing or actuation purposes in a living organism. The application of nanotechnology in the medical field is called nanomedicine. These can pass directly through the cellular membranes and interact with the cellular DNA and proteins, giving better desired results as compared to the traditional form of medicines. These nanomedicines are normally used across applications
Future Analysis of the Bacterial Vaginosis Drugs Market Research Report Study By …
This report researches the worldwide Bacterial Vaginosis Drugs Market cover complete aggressive standpoint including the overall market, key trends, opportunities, and key statistics on the market status of the leading market players. The scope of the report extends from market scenarios to comparative pricing between major players, cost and profit of the specified market regions. Scope of the Report: Bacterial vaginosis is an imbalance of "good" and "bad" bacteria in the vagina,